United States Drug Patent 6,099,863: Claim Scope, Expiration, Litigation and Galantamine Patent Landscape

U.S. Patent No. 6,099,863 protects a specific immediate-release galantamine hydrobromide tablet formulation and a dry-blending tableting process. Its central limitations are the 75:25 spray-dried lactose monohydrate/microcrystalline cellulose diluent, a cross-linked polymeric disintegrant, and defined excipient and concentration ranges. The patent issued on August 8, 2000, and its enforceable term expired in February 2017, subject to any applicable patent-term adjustment. The patent therefore creates no current U.S. barrier to generic galantamine tablets, although its claim structure remains relevant to historical ANDA litigation and freedom-to-operate analysis.

What does U.S. Patent 6,099,863 cover?

The patent covers a solid oral tablet containing galantamine hydrobromide in a particular excipient system. The independent claims are directed to both the product and the manufacturing process.

Claim	Subject matter	Principal limitations
1	Tablet composition	Therapeutically effective galantamine hydrobromide; spray-dried lactose monohydrate/microcrystalline cellulose at 75:25; insoluble or poorly soluble cross-linked polymer disintegrant
2	Tablet composition	Claim 1, with crospovidone or croscarmellose
3	Tablet composition	Claim 1, with a glidant and lubricant
4	Tablet composition	Colloidal anhydrous silica as glidant and magnesium stearate as lubricant
5	Quantitative composition	2-10% active; 83-93% diluent; 0.1-0.4% glidant; 3-8% disintegrant; 0.2-1% lubricant
6	Preferred quantitative composition	Approximately 0.2% silica, 5% crospovidone and 0.5% magnesium stearate
7	Coated tablet	Claim 1 with a film coat
8	Film coating	Film-forming polymer and plasticizer
9	Coating weight	About 3-8% of the uncoated core
10	Manufacturing process	Dry blending, optional lubricant addition, dry compression and optional film coating

The patent does not claim galantamine as a molecule, galantamine hydrobromide generally, or every oral dosage form containing galantamine. It claims a formulation architecture with specific excipient and processing requirements.

How should the independent composition claim be construed?

Claim 1 requires the accused product to contain each of the following:

Galantamine hydrobromide in a 1:1 salt form.
A therapeutically effective amount of that active ingredient.
A pharmaceutically acceptable carrier.
A spray-dried mixture of lactose monohydrate and microcrystalline cellulose.
A 75:25 ratio for the lactose/microcrystalline cellulose mixture.
An insoluble or poorly soluble cross-linked polymer disintegrant.

The claim uses “comprises,” which generally makes the composition open-ended. A product can contain additional excipients and still fall within the claim if it contains every required element. The open-ended language does not eliminate the need to prove the specific spray-dried 75:25 diluent and the required disintegrant.

What is the importance of the 75:25 spray-dried diluent?

The spray-dried physical mixture is a material limitation, not merely a list of ingredients. A tablet containing lactose monohydrate and microcrystalline cellulose separately may not meet the claim if the materials are not present as the claimed spray-dried mixture.

This limitation can be important in generic-product analysis because excipient labels and regulatory submissions may identify lactose and microcrystalline cellulose without disclosing whether the material was manufactured as a spray-dried composite. Batch records, supplier specifications, formulation development files and process validation records may be required to determine infringement.

What does “1:1” galantamine hydrobromide mean?

The claim is directed to the defined galantamine hydrobromide salt form, rather than an unspecified galantamine salt or free base. The 1:1 terminology identifies the stoichiometry of galantamine to hydrobromide. A product containing a different salt or a different stoichiometric form would present a distinct claim-construction issue.

The claim does not require a particular tablet strength. Claim 5 supplies percentage ranges, but claim 1 reaches a broader therapeutically effective amount if the remaining formulation elements are present.

Which dependent claims create the narrowest infringement positions?

Claims 5 and 6 are the most formulation-specific claims. They require a defined percentage profile and provide a more concrete basis for comparison with a finished product.

Claim 6 is narrower than claim 5 because it identifies preferred excipients and approximate concentrations:

2-10% galantamine hydrobromide;
83-93% spray-dried 75:25 lactose/microcrystalline cellulose;
approximately 0.2% colloidal anhydrous silica;
approximately 5% crospovidone; and
approximately 0.5% magnesium stearate.

The use of “about” in claim 6 introduces a tolerance question. The allowed range would depend on intrinsic evidence, prosecution history, formulation practice and the technical meaning of the term in the patent. “About 5%” is not automatically limited to exactly 5%, but it also does not make every disintegrant concentration equivalent.

Claim 9 narrows the film-coated product by requiring a coating weight of approximately 3-8% of the tablet core. A film-coated galantamine tablet with a coating outside that range may avoid claim 9 while remaining potentially relevant to claims 1, 7 or 8.

What process does claim 10 protect?

Claim 10 covers a dry tableting process involving:

Dry blending the active ingredient, disintegrant, optional glidant and diluent.
Optionally adding the lubricant.
Compressing the blend in the dry state.
Optionally applying a film coat.

The process claim is significant because it does not require wet granulation. A manufacturing process based on aqueous or solvent granulation may avoid the literal process limitations, even if the resulting tablet has a similar composition. That would not necessarily avoid the composition claims.

The claim language also creates a dependency issue. Claim 10 refers to a tablet “according to claim 3,” while the process text describes the glidant as optional and does not expressly require the lubricant to be added before compression. The scope would turn on the interaction between the dependent-claim reference and the process steps. A process using direct compression, dry blending and the claimed excipient system would have presented the closest historical infringement risk.

When did U.S. Patent 6,099,863 lose exclusivity?

The patent issued August 8, 2000. Its term was tied to the earliest relevant nonprovisional or international filing date in the family, generally producing an expiration date in February 2017. Public patent databases identify the patent as expired based on lifetime. The patent is therefore no longer an enforceable exclusionary right in the United States. [1][2]

Event	Date or period
Earliest relevant priority period	February 1996
U.S. filing period	February 1997
U.S. patent grant	August 8, 2000
Expected 20-year term endpoint	February 2017
Current status	Expired

The expiration analysis should distinguish patent expiration from regulatory exclusivity. FDA marketing exclusivity for the original galantamine product ended separately from the patent term and did not extend the patent.

What was the FDA regulatory status of galantamine?

Galantamine hydrobromide was approved in the United States for the treatment of mild-to-moderate Alzheimer’s disease under the Reminyl brand, later marketed as Razadyne. The reference product included immediate-release tablets, oral solution and extended-release capsules. FDA approval records and labeling identify Janssen as the original sponsor of the U.S. product. [3][4]

Regulatory issue	Status
Active ingredient	Galantamine hydrobromide
Original U.S. brand	Reminyl, later Razadyne
FDA indication	Mild-to-moderate Alzheimer’s disease
Immediate-release tablets	Approved
Oral solution	Approved
Extended-release capsules	Approved
Generic pathway	ANDA approval for equivalent dosage forms
Biologic pathway	Not applicable

Galantamine is a small molecule, not a biologic. Biosimilar risk does not apply. Competitive entry occurs through the generic-drug pathway, primarily under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

What is the Orange Book status of U.S. Patent 6,099,863?

The Orange Book is the relevant source for patents submitted for listed drug products and for associated use codes. Historical Orange Book records and FDA patent-listing data should be reviewed by product and NDA because a patent number can be listed against one dosage form or indication and not another. [5]

The practical conclusions are:

Patent 6,099,863 is expired.
It cannot currently delay approval of an ANDA through an unexpired patent listing.
Historical Paragraph IV certifications may have been relevant before expiration.
The patent did not create a current barrier to generic galantamine approval after its term ended.
Any remaining regulatory exclusivity would have had to arise from a separate FDA exclusivity provision, not from this expired patent.

The patent’s claims are formulation claims. They do not inherently cover every galantamine product listed in the Orange Book, including extended-release products with different release mechanisms.

Which companies challenged or competed against the galantamine reference product?

Generic competition developed around galantamine tablets, oral solution and extended-release formulations after the relevant FDA exclusivity and patent barriers diminished. Generic manufacturers in this market have included major ANDA sponsors such as Teva, Mylan, Sandoz, Dr. Reddy’s, Apotex and other suppliers, depending on dosage form and approval period. FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations identifies approved products and sponsors. [5]

A company’s approval of a galantamine ANDA does not by itself establish that it infringed or challenged Patent 6,099,863. ANDA certification records, Paragraph IV notices and district-court dockets are required to connect a specific applicant to a specific patent challenge.

No current Paragraph IV risk remains against this patent because the patent has expired.

What patent litigation and settlements affected galantamine?

The key litigation risk associated with Patent 6,099,863 was historical, not current. Before expiration, a generic applicant could have faced claims directed to:

use of the claimed spray-dried diluent;
use of crospovidone or croscarmellose;
the defined silica and magnesium stearate system;
the quantitative ranges in claims 5 and 6; and
dry blending and direct compression under claim 10.

A Paragraph IV certification could have triggered litigation under 21 U.S.C. § 355(j)(5)(B)(iii). If the NDA holder sued within the statutory period, FDA approval could have been stayed for up to 30 months, subject to statutory exceptions. [6]

The available patent record does not establish a current enforceable dispute involving this patent. Historical settlement terms, launch dates and license provisions must be tied to a specific ANDA applicant and docket. A commercial relationship involving Janssen, Shire or other galantamine participants does not, without a patent-specific agreement, prove a license under Patent 6,099,863.

What formulations are protected by the patent?

The strongest literal-coverage case involves an immediate-release compressed tablet with the following profile:

Formulation element	Claimed requirement
Active	Galantamine hydrobromide, 1:1
Diluent	Spray-dried lactose monohydrate/microcrystalline cellulose
Diluent ratio	75:25
Disintegrant	Insoluble or poorly soluble cross-linked polymer
Preferred disintegrant	Crospovidone or croscarmellose
Glidant	Colloidal anhydrous silica
Lubricant	Magnesium stearate
Manufacturing	Dry blending and dry compression
Coating	Optional film coat
Coating weight	Approximately 3-8% of core for claim 9

The patent does not expressly require a particular release profile, tablet strength, color, shape, dissolution specification or packaging format. It also does not claim a capsule shell, transdermal system, injectable product or a general method of treating Alzheimer’s disease.

How strong was the patent estate?

Claim strength

The patent had moderate historical formulation strength but limited breadth. Its principal strength came from the combination of several technical limitations:

a defined spray-dried diluent;
a specific excipient ratio;
a cross-linked polymer disintegrant;
direct-compression processing; and
quantitative formulation ranges.

The same limitations also narrowed the claim. A generic applicant could design around the patent by changing the diluent, using a different physical form of lactose or microcrystalline cellulose, selecting a non-cross-linked disintegrant, using wet granulation, or altering the excipient percentages.

Enforceability

Because the patent expired in 2017, enforceability is no longer a current commercial issue. During its term, validity questions could have focused on written description, enablement, obviousness over direct-compression tablet technology and earlier galantamine formulations, and the scope of the spray-dried excipient limitation. The claims appear directed to a defined formulation and process rather than a broad therapeutic invention.

Geographic coverage

U.S. Patent 6,099,863 provided protection only in the United States. Foreign counterparts may have existed in the same international family, but foreign rights required separate examination of national-phase grants, term adjustments, maintenance fees and local litigation. Expiration of the U.S. patent does not establish the status of corresponding European, Canadian, Japanese or other patents.

How does Patent 6,099,863 compare with other galantamine patent categories?

Patent category	Typical protected subject matter	Relevance to Patent 6,099,863
Active-ingredient patents	Galantamine molecule or salt	Not covered by this patent
Immediate-release formulation patents	Tablet excipients and compression process	Core subject of this patent
Extended-release patents	Multiparticulates, coatings, release-controlling matrices	Separate estate
Method-of-use patents	Alzheimer’s treatment and dosing regimens	Not claimed here
Manufacturing patents	Synthesis, purification or salt formation	Not claimed here
Regulatory exclusivity	FDA statutory market protection	Separate from patent rights
Generic product approvals	Therapeutically equivalent dosage forms	Current competitive pathway

The most important competitive distinction is between immediate-release tablets and extended-release products. A generic extended-release capsule may face a different patent estate and different product-specific FDA requirements even though it contains the same active ingredient.

What generic launch risks remain?

For Patent 6,099,863 itself, the patent-related launch risk is zero because the patent is expired. Current commercial risks are more likely to involve:

manufacturing cost and supply reliability;
FDA approval of the relevant dosage form;
therapeutic-equivalence requirements;
product-specific labeling;
remaining patents covering other galantamine formulations;
trademark and trade-dress issues;
controlled access to specialized excipients; and
price erosion from multiple generic suppliers.

The patent may still be relevant in due diligence as evidence of the formulation history of the reference product. It should not be treated as a live blocking right.

Key Takeaways

U.S. Patent 6,099,863 claims a galantamine hydrobromide tablet and direct-compression process.
The principal limitation is a spray-dried 75:25 lactose monohydrate/microcrystalline cellulose diluent combined with a cross-linked polymer disintegrant.
Claims 5 and 6 add narrow quantitative excipient ranges.
Claims 7-9 cover optional film coating and coating weight.
Claim 10 covers dry blending, dry compression and optional coating.
The patent does not claim galantamine generally, Alzheimer’s treatment generally, or extended-release galantamine products.
The U.S. patent expired in February 2017.
No current Paragraph IV or Orange Book barrier remains under this patent.
Galantamine is a small molecule, so biosimilar analysis is irrelevant.
Current generic competition depends on FDA-approved dosage forms and any separate, unexpired formulation or method-of-use rights.

FAQs About U.S. Patent 6,099,863

Can a generic use crospovidone in a galantamine tablet today?

Yes. Expiration of Patent 6,099,863 removes this patent as a current restriction, although other unexpired rights and FDA requirements must be assessed separately.

Does the patent cover galantamine extended-release capsules?

No. The claims are directed to tablets and a dry-compression process. Extended-release capsules require separate claim and patent-family analysis.

Does changing the lactose-to-cellulose ratio avoid the patent?

Potentially. The 75:25 spray-dried mixture is a material limitation in claim 1. A different ratio or a different physical form may avoid literal infringement, subject to equivalents analysis and the patent’s prosecution history.

Was a license required to sell generic galantamine after 2017?

Not under the expired U.S. Patent 6,099,863. A separate license could still have been relevant to other patents, trademarks, data rights or commercial arrangements.

Is Patent 6,099,863 relevant to a galantamine oral solution?

The issued claims require a tablet. An oral solution ordinarily would not meet the tablet limitation, although separate patents or regulatory requirements could apply.

References

United States Patent and Trademark Office. (2000). U.S. Patent No. 6,099,863, pharmaceutical compositions containing galanthamine.
Google Patents. (n.d.). US6099863A: Pharmaceutical compositions containing galanthamine.
U.S. Food and Drug Administration. (2001). Razadyne (galantamine hydrobromide) prescribing information.
Janssen Pharmaceuticals, Inc. (2010). Razadyne and Razadyne ER prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	96201676	Jun 14, 1996

PCT Information
PCT Filed	June 06, 1997	PCT Application Number:	PCT/EP97/02986
PCT Publication Date:	December 18, 1997	PCT Publication Number:	WO97/47304

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	008237	⤷ Start Trial
Argentina	070670	⤷ Start Trial
Austria	285777	⤷ Start Trial
Australia	3174397	⤷ Start Trial
Australia	726212	⤷ Start Trial
Bulgaria	102991	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,099,863

Summary for Patent: 6,099,863